IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Aisling Capital Management LP

Q1 2020 Holdings

Filed 2020-05-11 | 14 holdings | $121.1M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
BridgeBio (Bbio)(BBIO)COM10806X102$115.7M3,989,41295.5%
Arcus Biosciences, Inc. (Rcus)(RCUS)COM03969F109$4.6M333,3333.8%
Aclaris Theraputics Inc (Acrs)(ACRS)COM00461U105$660.0K634,4550.5%
Eidos Therapeutics, Inc. (Eidix)(EIDXGBP)COM28249H104$55.0K1,123,6300.0%
Avrobio, Inc. (Avro)COM05455M100$15.7K1,009,7790.0%
Syndax Pharmaceuticals Inc. (Sndx)(SNDX)COM87164F105$9.6K875,0000.0%
Atreca (Bcel)(BCELUSD)CL A COM04965G109$6.4K387,6530.0%
Aeglea Biotherapeutics Inc (Agle)(AGLEUSD)COM00773J103$6.0K1,291,1510.0%
Sunesis Pharmaceuticals, Inc. (Snss)COM867328700$4.2K10,100,0000.0%
Marker Therapeutics, Inc. (Mrkr)COM57055L107$3.8K2,000,0000.0%
ObsEva SA (Obsv)COMH5861P103$3.3K1,386,3380.0%
Verona Pharma plc (Vrna)(VRNA)COM925050106$1.8K443,5960.0%
Zosano Pharma Corporation (Zsan)COM98979H202$1.5K2,718,2260.0%
Nabriva Therapeutics plc (Nbrv)SHSG63637105$1.1K1,910,2870.0%